BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24316555)

  • 21. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
    Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
    Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.
    Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M
    J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    Donskov F; von der Maase H
    J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
    Olioso P; Giancola R; Di Riti M; Contento A; Accorsi P; Iacone A
    Hematol Oncol; 2009 Sep; 27(3):130-9. PubMed ID: 19294626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma.
    Jäkel CE; Hauser S; Rogenhofer S; Müller SC; Brossart P; Schmidt-Wolf IG
    Clin Dev Immunol; 2012; 2012():473245. PubMed ID: 23193418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
    Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
    Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
    Shablak A; Hawkins RE; Rothwell DG; Elkord E
    Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
    Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
    Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous cytokine-induced killer (CIK) cell immunotherapy combined with cyclophosphamide in five patients with POEMS syndrome.
    Ma L; Wang Y; Bo J; Han W; Wang Y; Zhang L; Wu X; Yu S; Liu R
    Clin Exp Immunol; 2016 Apr; 184(1):83-9. PubMed ID: 26660736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.